TrialEuropean urology2022

Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.

Maria I Carlo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.